share_log

Kymera Therapeutics Receives FDA Orphan Drug Designation For KT-333, A First-in-Class, Investigational STAT3 Degrader For The Treatment Of Cutaneous T-Cell Lymphoma

Kymera Therapeutics Receives FDA Orphan Drug Designation For KT-333, A First-in-Class, Investigational STAT3 Degrader For The Treatment Of Cutaneous T-Cell Lymphoma

Kymera治療公司獲得FDA的KT-333孤兒藥物稱號，KT-333是治療皮膚T細胞淋巴瘤的一流研究用STAT3降解劑
Benzinga Real-time News ·  2022/09/15 07:32

Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to KT-333 for the treatment of Cutaneous T-cell Lymphoma (CTCL).

凱美拉治療公司(納斯達克：KYMR)是一家臨牀階段推進蛋白質定向降解以提供新型小分子蛋白質降解劑藥物的生物製藥公司，該公司今天宣佈，美國食品和藥物管理局已授予KT-333治療皮膚T細胞淋巴瘤的孤兒藥物稱號。

KT-333 is a first-in-class degrader of the transcriptional regulator STAT3. Deregulation of STAT3 signaling has been implicated in the pathogenesis of a variety of cancers, including CTCL. There are currently no approved therapies for CTCL that target this pathway. KT-333 received orphan drug designation for the treatment of Peripheral T-cell Lymphoma (PTCL) earlier this year.

KT-333是轉錄調控基因STAT3的一種一流降解劑。STAT3信號的失控與包括CTCL在內的多種癌症的發病機制有關。目前還沒有針對這一途徑的CTCL已獲批准的治療方法。今年早些時候，KT-333獲得了治療外周T細胞淋巴瘤(PTCL)的孤兒藥物指定。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論